Private equity-backed One Medical launches IPO

San Francisco-based One Medical, a membership primary care company, has launched its initial public offering with a starting share price of $14. The company expected to gain gross proceeds of $245 million.

One Medical signaled in early January it was filing for an IPO. The company is backed by several high-profile private equity groups, including The Carlyle Group, GV (formerly Google Ventures) and J.P. Morgan. Its rise to an IPO underscores the booming private equity interest in the healthcare space. While the company has been touted as innovative and representing the future of healthcare, the company has yet to turn a profit, reporting a net loss of $34.2 million for the first nine months of 2019.

One Medical is a primary care company that is based on a membership model. Members pay $199 annually for access to primary care physicians and same-day appointments at its 77 physical offices in nine major U.S. cities. Patients also have access to virtual care at any time. The company launched in 2007 and has nearly 400,000 members in its ranks.

The company is trading on the Nasdaq under the moniker ONEM. 1Life Healthcare is the administrative and managerial services company for affiliated One Medical physician owned professional corporations, and both entities do business under the One Medical name, according to a press release.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

"The number of non-facility services reimbursed at less than direct costs grew 50% since 2024. The number of services under the MPFS for which reimbursement does not even cover cost likely is much higher than 300 services," the proposed AMA resolution states.

COVID-19 vaccines are associated with a very low risk of myocarditis and/or pericarditis, primarily in young adults. The long-term impact of this risk has been the subject of many studies and debates over the years. One side says that the benefits of vaccination far outweigh the risks, and the other side says that even the smallest risk of heart damage is too high.

Gerald G. Blackwell, MD, MBA, MedAxiom's president and CEO, examined how different cardiology employment models look today compared to even a decade ago.